Is it Time to Abandon Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation on Anticoagulation?

JACC Cardiovasc Interv. 2018 Apr 9;11(7):635-637. doi: 10.1016/j.jcin.2017.12.002. Epub 2018 Mar 14.

Authors

Jay Giri¹, Ashwin Nathan²

Affiliations

¹ Penn Center for Cardiovascular Outcomes, Quality & Evaluative Research, Cardiovascular Medicine Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: Jay.Giri@uphs.upenn.edu.
² Penn Center for Cardiovascular Outcomes, Quality & Evaluative Research, Cardiovascular Medicine Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

PMID: 29550087
DOI: 10.1016/j.jcin.2017.12.002

No abstract available

Keywords: PCI; antiplatelet therapy; atrial fibrillation; novel anticoagulants.

Publication types

Editorial
Comment

MeSH terms

Anticoagulants
Atrial Fibrillation*
Blood Coagulation
Humans
Percutaneous Coronary Intervention*
Platelet Aggregation Inhibitors

Substances

Anticoagulants
Platelet Aggregation Inhibitors